Payment overview · 2025
General Payments
$360.04
26 reported records · 4 companies
Healthcare provider profile · identity verified
Michael R Ford, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LITTLE ROCK, AR · NPI 1871502658
Verified facts
What the public records show
CMS Open Payments records show Michael R Ford, M.D. received $360.04 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 74.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $268.13 | 74.5% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.09 | 11.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.93 | 9.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.89 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $360.04 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $166.62 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $163.46 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.33 | 10 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 675 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 137 |
| Omeprazole | Omeprazole | 543 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 451 | 101 |
| Valsartan | Valsartan | 381 | 73 |
| Lisinopril | Lisinopril | 349 | 76 |
| Gabapentin | Gabapentin | 331 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 64 |
| Simvastatin | Simvastatin | 268 | 64 |
| Trazodone Hcl | Trazodone Hcl | 261 | 57 |
| Glipizide | Glipizide | 246 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 49 |
| Metformin Hcl | Metformin Hcl | 227 | 48 |
| Sertraline Hcl | Sertraline Hcl | 221 | 40 |
| Tramadol Hcl | Tramadol Hcl | 200 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 43 |
| Losartan Potassium | Losartan Potassium | 191 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 33 |
| Alendronate Sodium | Alendronate Sodium | 140 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 138 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 23 |
| Bupropion Xl | Bupropion Hcl | 115 | 26 |
| Furosemide | Furosemide | 113 | 25 |
| Meloxicam | Meloxicam | 113 | 23 |
| Potassium Chloride | Potassium Chloride | 113 | 29 |
| Famotidine | Famotidine | 112 | 26 |
| Allopurinol | Allopurinol | 106 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 22 |
| Alprazolam | Alprazolam | 95 | 30 |
| Montelukast Sodium | Montelukast Sodium | 90 | 17 |
| Mirtazapine | Mirtazapine | 87 | 19 |
| Prednisone | Prednisone | 82 | 62 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 29 |
| Doxepin Hcl | Doxepin Hcl | 79 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 23 |
| Atenolol | Atenolol | 68 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 15 |
| Clonazepam | Clonazepam | 67 | 19 |
| Pregabalin | Pregabalin | 66 | 13 |
| Amoxicillin | Amoxicillin | 65 | 54 |
| Diazepam | Diazepam | 65 | suppressed |
| Ozempic | Semaglutide | 65 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 17 |
| Metformin Hcl Er | Metformin Hcl | 64 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 39 |
| Eliquis | Apixaban | 61 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 61 | 11 |
| Donepezil Hcl | Donepezil Hcl | 59 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 43 |
| Estradiol | Estradiol | 54 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 15 |
| Clonidine Hcl | Clonidine Hcl | 51 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 13 |
| Labetalol Hcl | Labetalol Hcl | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Carvedilol | Carvedilol | 46 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 36 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Klor-Con M20 | Potassium Chloride | 43 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 37 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 20 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Fluconazole | Fluconazole | 37 | 21 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 30 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 15 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $360.04 · 26 records | ABBVIE INC. | AREXVY, OTEZLA, QULIPTA, REPATHA, SHINGRIX, UBRELVY, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error